1048041-42-4Relevant articles and documents
1,5-Benzodiazepine inhibitors of HCV NS5B polymerase
McGowan, David,Nyanguile, Origene,Cummings, Maxwell D.,Vendeville, Sandrine,Vandyck, Koen,Van den Broeck, Walter,Boutton, Carlo W.,De Bondt, Hendrik,Quirynen, Ludo,Amssoms, Katie,Bonfanti, Jean-Francois,Last, Stefaan,Rombauts, Klara,Tahri, Abdellah,Hu, Lili,Delouvroy, Frederic,Vermeiren, Katrien,Vandercruyssen, Genevieve,Van der Helm, Liesbet,Cleiren, Erna,Mostmans, Wendy,Lory, Pedro,Pille, Geert,Van Emelen, Kristof,Fanning, Gregory,Pauwels, Frederik,Lin, Tse-I,Simmen, Kenneth,Raboisson, Pierre
scheme or table, p. 2492 - 2496 (2009/12/07)
Optimization through parallel synthesis of a novel series of hepatitis C virus (HCV) NS5B polymerase inhibitors led to the identification of (R)-11-(4-benzyloxy-2-fluorophenyl)-6-hydroxy-3,3-dimethyl-10-(6-methylpyridine-2-carbonyl)-2,3,4,5,10,11-hexahydr
6-HYDROXY-DIBENZODIAZEPINONES USEFUL AS HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 50, (2008/12/08)
Inhibitors of HCV replication of formula (I) the stereoisomers, prodrugs, tautomers, racemics, salts, hydrates or solvates thereof wherein R1, R2; R3; R4a and R4b have the meaning defined in the claims.The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.
